Login to Your Account

Splitting the diff: Results soon from Seres phase II, pundit 'gut feeling' good

By Randy Osborne
Staff Writer

Friday, July 1, 2016

With new science and true innovation, reimbursement should "take care of itself," Seres Therapeutics Inc.'s chief scientific officer (CSO) David Cook told BioWorld Today, on the brink of phase IIb data with SER-109 for recurrent Clostridium difficile infection (CDI).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription